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Privacy Rule and Family Educational Rights and Privacy Act. The Delphi technique
was used to obtain expert input for the coding document. The 131 variable coding
instrument received 93.7% agreement and a K- of .791. RESULTS: Including all
subsections, 984 laws across localities relate to immunization records. Within and
across localities, laws were grouped into 13 topic headings, including health, edu-
cation, licensing, vital statistics, and insurance. Of 36 (64%) localities that have laws
addressing IIS creation, 42% authorize and 58% require development. Locality
adoption of these laws increased 50% since the previous study. While 24 (43%)
localities have specific IIS laws, 34 (61%) have IIS provisions within other laws.
Many others may not specify IIS, but do regulate collection, sharing and/or storage
of immunization data within education, department of health or other records.
Aggregate data for the localities is presented in tabular format and shaded maps.
CONCLUSIONS: Locality IIS policies have increased, HEDIS measures incorporate
childhood immunizations, and now Meaningful Use incentives include IIS partic-
ipation. Expanding adoption of policies encouraging participation may suggest a
diffusion of innovation, through both national and state channels. As entrepreneur
localities experiment to improve IIS utility and uniformity, it will be important to
consider how the current framework has influenced participation, and opportuni-
ties for future coordination through policy development.
Infection – Research on Methods
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COMPARISON OF EVIDENCE-BASED VARIATION AND CONSTANT PERCENTAGE
VARIATION FOR ONE-WAY SENSITIVITY ANALYSES
McQueen RB, Libby A, Campbell J
University of Colorado, Aurora, CO, USA
OBJECTIVES: A common approach to one-way sensitivity analysis is to vary inputs
by a constant percentage. An alternative is to derive ranges using evidence-based
probability distributions from published sources. Our objective was to compare
one-way sensitivity analysis results when using these two approaches in the same
decisionmodel.METHODS:We replicated a published HIV/AIDS cost-effectiveness
Markov model (zidovudine vs. zidovudine plus lamivudine in the UK) using Tree-
Age®. Health states included three HIV/AIDS states and death. We generated one-
way sensitivity analyses by varying inputs in twoways: 1) using15% for all inputs,
and 2) using the 2.5 and 97.5 percentile values of the evidence-based probability
distributions for all inputs.We compared the decisionuncertainty in the incremen-
tal cost-effectiveness ratios (ICERs) for each variation method as reflected by the
difference of the lower and upper range of ICERs for all inputs. Our outcome of
interestwas themeandifference in ICERuncertaintybetweeneachmethod for the ten
most influential inputs. Additionally, we assessed the number of inputs that would
have led to an inconclusive decision for eachmethodwherehighdecisionuncertainty
exists (e.g., in this example, a willingness-to-pay (WTP) of £10,000/QALY). RESULTS:
The deterministic ICER was £7,654/QALY for combination therapy vs. mono-
therapy. Themean difference in ICER uncertainty for the evidence-based vs.15%
variation method was £3,251/QALY (p0.0096). At a WTP of £10,000/QALY, four
inputs would have led to an inconclusive decision to adopt combination therapy
using the evidence-based variation method compared to no inputs using the con-
stant percentage variation method. CONCLUSIONS: In this case, the magnitude of
uncertainty in the outcome was larger for the evidence-based variation method
compared to the constant percentage variation method. Evidence-based uncer-
tainty in inputs should be used in all sensitivity analyses to reflect realistic uncer-
tainty in an outcome and aid decision-making about future research strategies.
Muscular-Skeletal Disorders – Clinical Outcomes Studies
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DO BISPHOSPHONATES CAUSE ATYPICAL FEMUR FRACTURES?
Mann J, Talbert J
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Clinical case reports support the occurrence of atypical fractures
while Phase III trials for bisphosphonates have not shown this adverse effect. This
study determines whether or not atypical fractures of the subtrochanteric region
and diaphyseal femur are occurring in bisphosphonate users within the Kentucky
Medicaid population. The incidence of atypical femur fractures in bisphosphonate
users has been estimated at 30 per 100,000 person years.1 Bisphosphonates are
commonly prescribed for the prevention of osteoporosis-related fractures,2 but
there are concerns about this possible, but rare, adverse event related to the long-
term use of bisphosphonates.3,4 METHODS: The retrospective Kentucky Medicaid
claims based study assesses the risk of atypical fracture in bisphosphonate treated
patients versus non-bisphosphonate treated patients, who experienced a baseline
fracture. Of the 19,988 patients, aged 45-95, 2,440 of them used a bisphosphonate
for at least 180 days. RESULTS: There were 209 patients experiencing an atypical
fracture. Baseline fractures were grouped and those experiencing atypical frac-
tures versus those who didn’t are as follows: humerus (1.95% vs 0.97%), lower
extremity (3.04% vs 0.97%) and vertebral (1.58% vs 0.95%). Unadjusted analysis
indicated that bisphosphonate users are two times more likely to have atypical
fracture (OR: 2.2271 95% CI: 1.6123-3.0758). Adjusting for demographics, baseline
fracture, Charlson comorbidity index, and use of corticosteroids the patients who
used a bisphosphonate for at least 6 months were 1.92 times more likely to have
atypical fracture than non-users (95% CI: 1.365-2.688). Age was a significant predic-
tor in themultivariatemodel; bisphosphonate users, 65 and older,were three times
more likely to have an atypical fracture (OR: 3.187 p value0.001). CONCLUSIONS:
While a relationship between bisphosphonate use and atypical fractures is pres-
ent, the preventative function of other fractures dictates continued therapy. How-
ever, more research is needed to determine if a certain subtype of patients can be
identified to prevent future atypical fractures.
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BACKGROUND: Bisphosphonates have been associated with an increased risk of
atrial fibrillation (AF) and may thus be associated with an increased risk of cardio-
vascular (CV) events. However, recent studies have so far not confirmed the poten-
tial risk of CV events associated with bisphosphonate use. In addition, whether the
CV risk associated with continuous bisphosphonate use remains an unanswered
clinical question. OBJECTIVES: The purpose of this study was to assess the CV risk
including AF, stroke, or acute myocardial infarction in osteoporotic women ex-
posed to oral bisphosphonates for at least three months.METHODS:We used the
2000-2008 Taiwan’s National Health Insurance Program to conduct a popula-
tion-based, cross-over study of 10,572 newly diagnosed osteoporotic women.
Eligible patients were those who had taken alendronate, 10 mg or 70 mg, for at
least three months. Study subjects were further categorized into continuous
and discontinued users. Cox proportional models were used to compare the
1-year risk of CV events between continuous and discontinued users. RESULTS:
Among the 10,572 osteoporotic women, 8,852 received a weekly regimen of
alendronate 70 mg while 1720 received a daily regimen of alendronate 10mg.
More than 80% of alendronate users continued their therapy after the first three
months. The cumulative exposure of alendronate were 285 and 104 days (alen-
dronate 70mg) and 251 and 96 days (alendronate 10mg) in continuous and dis-
continued users, respectively. Compared to discontinued user, continuous
use of alendronate was not associated with a higher risk of CV events.
These findings were consistent among the users of alendronate 70mg
(HR1.06, 95%CI0.80-1.39) and alendronate 10mg (HR0.67, 95%CI0.42-1.06).
CONCLUSIONS: Continuous alendronate use was not significantly associated with
an increased CV risk in osteoporotic women.
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OBJECTIVES: To evaluate adoption of treatment guidelines recommending the ini-
tiation of a DMARD within 12 months of new RA diagnosis and to identify risk
factors for non-initiation. METHODS: Newly diagnosed adult RA patients from
2003-2009 with 12 months of continuous enrollment before and after their first RA
diagnosis were identified in the MarketScan Research Databases®. Patients were
excluded if they used a biologic or conventional DMARD prior to their first diagno-
sis. Patients were categorized as DMARD initiators or non-initiators in the 12
months following diagnosis (follow-up period). We compared demographic and
clinical characteristics of initiators versus non-initiators using Cox-proportional
hazard models. RESULTS: A total of 26,911 patients met the study criteria; 17,014
patients (63%) initiated a DMARD therapy in the follow-up period. At baseline, com-
pared to initiators, non-initiators were older [mean age 62.6 (SD14.9) versus 58.1
(SD13.3), p0.001], had a higher Deyo-Charlson Comorbidity Index Score (CCI) [0.76
(SD1.3) versus 0.58 (SD1.1), p0.001],weremore likely tohavehadan inpatient stay
in the pre-index period (19% versus 13%, p0.001), had higher pre-index total costs
[$12,725 (SD$24,500) versus $10,534 (SD$20,259), p0.001] and had similar out-of-
pocket total costs [$1,224 (SD$1,370) versus $1,230 (SD$1,519), p0.738)] and out-
of-pocket outpatient pharmacy costs [$492 (SD$611) versus $478 (SD$553),
p0.052]. Multivariate-adjusted risk factors for DMARD non-initiation included older
age (85), high CCI (3), and the presence of GI disorders, cardiac conditions, hyper-
tension, osteoarthritis, or respiratory infections in the pre-index period. Patients who
used an NSAID or corticosteroid, were diabetic, saw a rheumatologist, or had a rheu-
matoid factor test in the pre-index period were all more likely to initiate a DMARD in
the follow-up period. CONCLUSIONS: The majority of new RA patients followed
treatment guidelines and initiated a DMARD therapy; nevertheless, over one-third
of the patients did not initiate DMARD therapy within a year after diagnosis.
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THE ASSOCIATION BETWEEN TERIPARATIDE PERSISTENCE AND FRACTURE
OUTCOMES IN A US CLAIMS DATABASE
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OBJECTIVES: To evaluate the association between persistence on teriparatide
(TPTD) treatment and fracture incidence rate and fracture risk among US patients.
METHODS: We used the Thomson Reuters MarketScan® Research Databases,
2004-2008, to identify new TPTD users 18 years with continuous medical and
pharmacy coverage over 12-months pre-index and 24-months post-index date (in-
dex datefirst TPTD prescription). Pathologic fractures, traumatic or clustered
fracture events (3) occurring within 7 days, fractures within 90 days of index date
or at the same site, and any hip fractures after 2nd occurrence were excluded from
the post-index osteoporotic fracture definition. Persistence was measured as total
days on TPTD until first 45-day gap. Logistic regressions were performed to model
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